Amyris Inc (fka AMRSQ)

[2014shelby]

Is AMRS doing another RS? The PPS just keeps dropping

[finesand]

RSI lower-double-bottom turnaround play

(re-post of this colorful chart from ST)

Suggestion is, we are at a similar point as of 3/8,
which produced a lower bottom as of 2/2,
having a higher RSI.

Now on 8/16, we have a lower bottom and slightly higher RSI
compared to 6/21. Period is a bit stretched due to ER.

Also see the Ichimoko cloud removed resistance.

The above may conclude that we are becoming ready to a reversal again soon, if not even tomorrow.

[SubstitutedPinions]

Thanks for the info! Great work.

[finesand]

Compared to T-1 and T-2 cash inflow of around $200M or more, the stock's MCAP is less than half and EV just 2/3.

Compared to T-1 and T-2 cash inflow of around $200M or more, the stock's MCAP is less than half and EV just 3/2.

[finesand]

Found missing T-1 Equity & Liabilities Reduction.

(got this from a ST thread, nice DD)

Everybody might have expected a much better looking balance sheet 2Q17 due to the T-1 offering already and were disappointed.

Up until 7/7:
- DSM got 7.936M shares @ $7.425/sh $58.95M.
- Doerr/Naxos payed $65.2M = $25M + $40.2M debt for a not yet disclosed amount of shares and Cash Warrant conversion.

Maximum theoretical funding via T-1 and T-2 is:
T-1 Total: 27.73M @ $7.43/sh for $205.90M
T-2 Total: 12.38M @ $5.87/sh for $ 72.72M
Total: 40.11M @ $6.95/sh for $278.62M

The 10-Q states that only $31.20M cash and $40.20M debt reduction, total $71.4M, has been accounted in 2Q17 with OS 25.27M. Subsequently they mention $50M has been accounted for T-2 within 3Q17 with OS 37.61M.

The conversions hasn't been completed yet, not all Cash Warrants have been converted - more cash to come.

10-Q balance sheet didn't show an equity raise of anything close to $71.4M, but just some $12M.
The big question arises: Where is the money?

As mentioned above most of the shares to be offered were not yet converted.

The T-1 deal in May was structured in a very complicated manner. Shares couldn't be just issued, since they exceed the 20% threshold and a post deal SH meeting on 7/7 had to approve it. To secure the investor's ROI, a promise in dividend payments had to be given in case they had to keep the notes (preferred shares). Dividend payment would then be performed in common shares if conversion failed, hence more shares given if stock price goes lower.
This construct had to be modeled into the balance sheet as a level-3 derivative liability, see FAS 157 - Derivative valuation insights.

10-Q shows an increment of $51.128M in level-3 derivative liabilities, adding $58.606M to Total Liabilities due to some potential event of anti-dilutive conversion modeled.

The 2Q17 PR especially hints to the resolution

Included within other income for the second quarter was a gain of $35.8 million arising from the change in fair value of derivative liabilities recognized primarily in connection with the closing of the company's Series A and B financing rounds in May 2017. The net loss attributable to common stockholders included non-cash items such as a gain from changes in fair value of embedded derivatives, stock-based compensation expense, accretion of convertible preferred stock, and deemed and cumulative dividends to convertible preferred stockholders.

Possibly the whole difference of $59M or more has been dropped as derivative liabilities in regards to the T-1 offering, reducing Equity and increasing Total Liabilities and hence EV.
However, in the followup financials only $45M were being used.

In the 2Q17 CC, CFO emphasized

As a reminder, the preferred stock sold in both tranches will be automatically converted to common stock October 7, which is 90 days following our shareholder approval, July 7

."

Meaning on 10/7 all T-1 and T-2 conversion at the fixed price of $6.95/sh average will be performed, the whole amount of cash booked, OS stated and last but not least the level-3 derivative liabilities removed from the book. That day will allow to make 4Q17 balance sheet look much nicer, we just cannot see it yet due to these regulations - but the mechanics are already planned and signed off.

The adjustment of $45M shows an equity raise of around $57M, voila, as mentioned above, this is a lower figure.
This also reduced EV @ $2.40 from $356M to $313M, which is essential for the revenue multiple evaluation!

Compared to T-1 and T-2 cash inflow of around $200M or more, the stock's MCAP is less than half and EV just 2/3.
Further, this is the lowest ever EV recorded for this company (taking out it's high bankruptcy risk within 3Q16).

The company is in a better position than it ever was, especially with DSM on board as a partner and BOD. Vivo as a new long time investor also gives a high level of confidence.

This stock is at the very least worth double it's current trading price to match the new capitalization. Actually triple, since there was a value before the new investment.


Also have a look at the previously mentioned blog contemplating about the fair bottom value.

The adjusted Fundamental sheet:


The original Fundamental sheet:

[finesand]

10-Q p9 Liquidity, let's quote properly:

The Company has incurred significant operating losses since its inception and expects to continue to incur losses and negative cash flows from operations into 2018. As of June 30, 2017, the Company had negative working capital of $21.8 million, an accumulated deficit of $1.2 billion, and cash, cash equivalents and short term investments of $6.6 million. These factors raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these financial statements are issued. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

The newly included statement has been emphasized, i.e. a hint where company intends to become cash flow positive! The other parts are not new, well known of course.

One more hint has been analyzed, as mentioned by CFO in CC.
Kathy said that on 10/7 the new preferred shares from recent T-1/T-2 will be converted (thx to SH approval). This will close the Cash Warrants and avoids paying dividends starting 10/13!
This is a very big positive, as we know - they are all out of the money, not that these long time investors want to sell, still. Average purchase price by $6.25/sh.

Where all the money from the offering is? Not yet included, more to come assuming a 55M maximum OS now instead of 64M.
So by 10/7 and hence within 4Q17 statement all will be written out. Appreciation of MCAP shall happen from here, read: recovery.

[finesand]

yup, sounds familiar. the re-capitalization sadly hasn't been recognized yet in this 10-Q. Hence the OS is still lower than estimated 55M - 64M. This will be fully reflected within 3Q17.

Also this pending recognition still kept the going concern phrase as known in the filing. However:
- it has been filed that it happened (re-capitalization)
- collab + product revenue on track now.

Also the 10-Q has been filed on time and matches the PR.
Removes the hysterical mood.

[PStockPickz]

As of June 30, 2017, the Company had negative working capital of $21.8 million, an accumulated deficit of $1.2 billion, and cash, cash equivalents and short term investments of $6.6 million

[finesand]

Fair Floor Value & 2Q17 Highlights..
See SA blog post from 8/11.

[XAVIPS]

Now d info u r posting is correct.
D future of this Co is amazing IMO

[finesand]

Almost bullish? re-reading your post again :)
Well, either believe DSM + Vivo who surely had a look into the details before making their premium investment or you may simply wait until 3Q17 to pay more for your stake.
I am surely hopeful at this point, for $130M+ good reasons.

[finesand]

- SI wise, you are correct.
- Otherwise: Just think about the investment inflow $130M (could be max higher) at high premium to current price (T-2).

If this is not confidence enough Sir, I don't know what is.

We know past performance sucked due to low margin bio-fuel
and company is still in early stage commercialization.

I have to question about your strong enthusiasm as a short here, almost a ridiculous obsession. Until the final declaration of latest offering was disclosed I also held back and knew the volatility will hit. The big unknown.
Now all is set up for growth w/o liquidity issues, your ongoing bearish sentiment still gets noticed, but wiped away by the big premium investment.

Time to follow the vision again Sir.

I hope you are aware that there is a strong market for synthetic biotech companies? IMO Amyris is now better positioned than XON.

The year long experience of this company, yes - even the failures, will help making this a success story while standing on strong shoulders!

[Spider Web]

UPDATED INFORMATION


APPROX SHORT INTEREST
Short Per Nsdq = 1.76M
Float Per Finviz = 13.89M
Closer To 13% ---> Not 64%


THREE WAYS TO PROFIT
1) Higher Revenues
2) Better Margins
3) Lower Expenses


1) HIGHER REVENUES
Product + Collaborations ---------> Total
Q1-2016 = $03.1M + $05.7M ---> $08.8M
Q2-2016 = $04.9M + $04.7M ---> $09.6M
Q3-2016 = $06.8M + $19.7M ---> $26.5M
Q4-2016 = $11.5M + $10.8M ---> $22.3M
FY-TOTAL = $26 + $41 ----------> $67M

Q1-2017 = $08.3M + $04.7M ---> $13.0M
Q2-2017 = $12.7M + $13.0M ---> $25.7M
FY-EST = $60M + $55M ---------> $115M


2) BETTER MARGINS
Q1-2016 = (300%)
Q2-2016 = 18%
Q3-2016 = 44%
Q4-2016 = (2%)
Q1-2017 = 2%
Q2-2017 = 33%


3) LOWER COSTS AND
OPERATING EXPENSE
COGS + R&D + SG&A
Q1-2016 = $35M
Q2-2016 = $33M
Q3-2016 = $38M
Q4-2016 = $57M
Q1-2017 = $40M
Q2-2017 = $48M
This Will Follow


LEADING TO PROFITS
IMPROVED EARNINGS
Pre-Split -------------> Post-Split
Q1-2016 = ($0.07) ---> ($1.11)
Q2-2016 = ($0.06) ---> ($0.91)
Q3-2016 = ($0.08) ---> ($1.19)
Q4-2016 = ($0.18) ---> ($2.68)
Q1-2017 = ($0.13) ---> ($1.94)
Q2-2017 = ($0.03) ---> ($0.46)



COMMENTS

Improved Revs + Margins + Earnings
Revenues Increased To Almost $26M ,
Second Best In The Company's History.
Then The Gross Margin Jumped To 33% ,
Second Best In The Company's History.
Pre-Split EPS = ($0.03) & 10 Cents Better ,
The Best EPS In The Company's History.

The "Post-Split" EPS Number Equals ($0.46) ,
Which Beat The Analyst Estimates Of ($1.23) .
That Estimate Was Beat By 77 Cents, Or 63% .


Technicals Are Setting Up
Double, Maybe Triple Bottom On Volume.
Oversold With A Double Pincher Pattern.


Getting Their Act Together
Product Revenues Are Starting To Ramp Up ,
More And Better Collaborations On The Way.
Gross Margins Are Stabilizing And Improving.
Total Costs & Operating Expenses Will Drop.


2016 TOTAL ACTUAL REVENUES
Product $26M + Collaborations $41M = $67M

2017 TOTAL REVENUE ESTIMATES
Product $60M + Collaborations $55M = $115M

2018 PRODUCT REVENUE TO DOUBLE
Plus More & Better Collaborations & Catalysts

Similar To Last Year, But No Pump-n-Dump.
No More Tricks Lurking In The Background.


JMO

[finesand]

Reading the ongoing analysis and evaluation over this weekend, I cannot stop laughing about Friday's dip and truly have to thank all the shorts or who-ever who made this happen.

- 2Q17 a double beat
- 64% of float shorted (holy moly)
- EV now just about offering investment, should be double
- 2018 $16/sh @ EV/R 3 only, bottom evaluation
- ..

Now I have tears of laughter in my eyes and I have to stop typing, not to creating a short circuit in my keyboard :)

[finesand]

Now I understand where you're low PT is coming from.

Summer 2016 depressed price of around $4.65 happened due to lack of revenue starting in 2015. Company also had a liquidity crisis and indeed Bankruptcy could have been a possibility.
The negative sentiment was hard to cure, as always, it takes multiple quarters to repair previously done damage.

The T-1 and T-2 dilution lead to a retention of around 30% of pre-dilution value, hence $4.65 depressed lows equals $1.40.

Well, company is no more under bankruptcy risk for almost one year - and on filed paper for like 8 month.
Latest debt restructuring and re-capitalization removed all doubts about it, especially since they are now fully funded and won't need to find customers handing them out money upfront.
IMO this is a very important part of the equation.

Now we can look at the pre-dilution $8 bottom, equaling to $2.40 today. And it hit! Is that price reasonable at all?
I don't think so, since it reflected a bad ER outlier with the confusion of the impact of this offering as well as the RS depression. Previously the selling insider Temasek also pushed the price down, all these headwinds are gone now.

The offering took away debt and hence moved value to equity, book wise. Not even mentioning DSM's long term positive impact regarding revenue.

As of now, we are looking at a healthy company, financials being fixed and ready to fulfill its high margin product value share and collaborations.

No more biofuel

[SubstitutedPinions]

Careful. Best approach reality slowly...

[treppy]

Spidey, you're saying that the projections are worse yet you yourself predicted it at 1.25 and now you are suggesting it is at 1.50 so by your own inclination you see this getting better not worse.

[XAVIPS]

Second quarter total revenue of $25.7 million was 168% greater than the second quarter of 2016. Product sales were up 159% year-over-year and 53% on a sequential basis.
Second quarter revenue of $25.7 million includes $12.7 million of product revenue and $13 million of collaboration revenue. This result is better than the target of doubling prior year revenue - prior year quarter product revenue and better than 2017 plan to date and the performance of most other companies in Amyris space.
This is not my opinion, it is copy paste from actual statements right after Q2 results yesterday.
I would like Spiderweb to back up his "opinions".
But d best is yet to come... their great science, is starting to payoff...
They've been significantly reducing debt, they have new big investors with whom they have product collaboration agreements, focusing on high demand-high margin products, and so much more in the pipeline... new plants to increase production coming soon, etc. The sweetner, perfume molecules, pharma, tyre industry, food... you name it.
This company is gonna be huge in d near future IMO of course.
Just wait and see...

[finesand]

you should clean your ears a bit: 'double or better' even the CFO said, while low-balling expectations to not create another Melo disaster.

Performance compared w/ current MCAP assuming 64M OS fully diluted -> this stock is very cheap right now.

Recovery should indeed match last purchase price $4.26, equaling $14 pre-dilution or around $1 pre-RS.

When you realize the progress being made incl. production facilities and many not-mentioned items .. you will know what you have bought.

Hint: High overall revenue w/o much collaboration cash, while margins are low due to pending profit shares payout with higher margins. Also: DSM impact 2018-2019.

[Spider Web]

PROJECTIONS GETTING WORSE

The Original Revenue Projection Was
$200M This Year And A $100M First-Half

Then That Was Recently Reduced To
$120M This Year And A $60M First-Half

But Now The Actual Numbers Show
$77M This Year And A $38M First-Half

They May Have Also Finished Collecting The
Rest Of Those Collaboration Revenues Due
From Last Year, At $13M. And Those Last
Final Payments Should Now Be Over With.

WORTH ONE DOLLAR AND FIFTY CENTS

With The Current Revenue Projections And
Shr Structure, Combined With The Available
Cash, Debt, And Low Margins... This Stock
Is Currently Worth Between $1.25 & $1.75 .

NO PROFIT ---> NO CASH
BAD DEBT ---> NO REVENUES
DILUTION ---> ANOTHER SPLIT

Their Primary Job Is To Trick You


JMO

[White Coal]

I think you're on to something here. I'm not knowledgeable enough in AMRS to give an honest take however.

I will likely join soon.

Good luck Oger

Always fun watching shorts fry :)

[Oger]

White coal. What's your take? Great quarter! Huge shorting for long time.
Should bounce good tomorrow.
Good luck as well

[White Coal]

Rad! Good luck. Hit me back when it gaps to $8..

Thx!

[Oger]

$4 Friday !!!!!!!

[Spider Web]

BUY LOW ---> SELL LOWER

T R A P P E D

:--- |

[ShadowSpy69]

.... btw real cool of you. cool cat

[White Coal]

"Easily a gap filler $8 and launch to low teens imo is brewing!"

OUCH!

Watch your wallets folks

[TheSerb]

FOUND A WAY OUT! BUY LOW, SELL HIGH!!

[finesand]

T2 deal out, concerning $4.26/sh to Vivo,
which is below the $6.30 anti-dilutive Warrants triggering point.

Followed a few convos about this and conclusion seems to be:
- the $7+ goal due to DSM & Co buying at that price is gone
- even more dilution using these Warrants, avg down

The end game is not so clear here, but for sure won't increase the value for common, esp since investors now have an incentive to even short this stop down for lower conversion - at least temporarily.

Regardless whether they do that - the company has dropped the other shoe with that offering to Vivo, where they promised not to do so - promised no surprise.

Depressing, sold all shares today.

They seemingly are in dire distress to require the $25M from Vivo, even triggering the anti-dilutive threshold.

[TheSerb]

ALWAYS A WAY OUT

AMRS

[Spider Web]

NO WAY OUT

DEBT --->
DILUTION --->
REVERSE-SPLIT

The First Quarter Was Really Bad.
The Second Quarter Will Be Worse.

According To The Geniuses That Work
For This Company, The First Six Months
Of 2017 Should Show $100M In Revenues.

But Wait... They Recently Backtracked
On All Of That (As Usual), To Now $60M !

HOLD THE PHONE !!!
They Will Be Lucky To Show $30M ... LOL
Then They Will Adjust Projections Again !

If They Keep Adjusting Projections Lower,
Then One Day They Can Start Increasing
Them Again ... LOL - Ha! Ha! Ha! - LOL !!!


CALCULATING THE PPS
There Is No Calculation For The PPS. It Is Simply The Amount That Investors Are Willing To Pay For One Shr. The PPS Can Also Be Determined By Supply And Demand. The Company's Future Growth Does Not Look So Good: Therefore, Demand Is Low And Supply Is Growing Each Day. That Is Why The PPS Is Heading Down. Any PPS Appreciation Will Only Happen After More Dilution And Another Reverse-Spilt ... Nothing Else Matters.


NOTHING TO LOOK FORWARD TO
With All Of Those Bad Collaborations And Back-Room Warrants & Convertible Preferred Stock Deals, The Common Shareholder Is Primed To Be Screwed Over And Over Again With More Dilution And Another Reverse-Split.

Any Debt That May Be Cleaned-Up Will Always Be At The Expense Of The Shareholders, Like What Just Recently Happened, As More New Debt Is Then Added. The End Game Here May Be To Collapse The Company And Then Reconstruct It Into A Private One, Leaving Everyone Else In The Dust. Most Of The Common People Out There In La-La-Land Cannot Begin To Comprehend The Messed-Up Complexities Of This Convoluted Vast Empty Vacuum. Which Is About To Suck Everyone Down Into Its Deepest Darkest Depths Of Mordor.


N O - P R O F I T
M O R E - D E B T
N O - R E V E N U E S
M O R E - D I L U T I O N
AND ANOTHER REVERSE-SPLIT

That's Right . . .

One Reverse Split Wasn't Enough
Now They Are Promising Two - LOL


:--- (

[treppy]

Appreciate the insight

[finesand]

Tranche-B and 2Q17 ER waiting game, blocking recovery.

One way to look at the current MCAP evaluation is by comparing it to past performance, i.e. P/S ratio or whatnot. In this view, the stock is surely undervalued. Especially if you look at DSM's purchase price above $7/sh of the last Tranche-A offering.

Another way to evaluate the stock is simply by applying conventional and conservative metrics, here the company still has a long way to go to prove its future profitability. We know that.
COGS versus product-sales must be improved for profits finally. The profit-sharing instrument will not hit the bell yet, as shown in last investor relation presentation. The cooperation- or research-income might get reduced. All this may cause a flatlined revenue until 2018, until the new production facility can become online.
Conservatively speaking, the debt ratios are still sub-optimal and there is still no equity available for common shareholders, i.e. total liabilities outweighs all assets.

Anyway we look at it, company got the 'paying forward' long term DSM investment at a good premium. They can be patient for 2018/19 turnaround game, due to the great technological advantage of this company.

How will the Tranche-B offering, around additional 5M shares for DSM at above $6.30/sh be received?

Price appreciation forward as DSM does may not happen in the open market until next year and we may see more roller-coasters. However, let's be ready for this company's turnaround story. May signs be visible EOY or early 2018.

[BottomBounce]

$AMRS U.S. Chemical Production Industry is Projected to Grow
Chemicals Stocks on Investors' Radar -- Dow Chemical, Huntsman, FMC Corp., and Gevo
OTC: $EESE, Gulf Resources, Inc. (NASDAQ: $GURE , Valhi, Inc. (NYSE: $VHI , Gevo, Inc. (NASDAQ: $GEVO ), Amyris Inc. (NASDAQ: $AMRS )

[TheSerb]

OUCH! SLIPPING INTO DARKNESS OT REALLY!

[treppy]

Please provide justification. Is your analysis to still hit $1.25?

[Spider Web]

SLIPPING INTO DARKNESS

That's Where It's Headed

:--- (

[stocktrademan]

AMRS buy 4.09

double bottom
bullish divergence
stochastics crossing up out of oversold
moving average golden cross pattern will alert even more buyers to check out the chart









normal chart




log chart

[finesand]

DSM payed $7.425/sh for 7.94M, $58.95M and is willing to buy more at the same price range using tranche-b.

(i) 3,968,116 shares of Common Stock issuable upon conversion of 25,000 shares of Series B Preferred Stock (@ $6.30/sh, S-B @ $1k)
(ii) 3,968,116 shares of Common Stock issuable upon exercise of the Cash Warrants (1.98M @ $7.80 and 1.98M @ $9.30) @ $8.55/sh

[ShadowSpy69]

lol up another 4+% and looking for a close over $4 tomorrow. Set to launch to $8 soon imo

[TheSerb]

D R E A M E R S A R E B E L I E V E R S!

NO ONE IS WATCHING THIS ANYMORE.

AMRS BUYING TIME!!!

[Spider Web]

D R E A M E R S

LOL - That Takes The Cake !!!
Better Do Some Research - LOL

Not All Gaps Are Filled . . .
Especially When The Company
Is A Lying Massive Piece Of Junk.

But I Know, I Know . . .
You're A Gambler. It Hit That 50-MA
And You See That 200-MA Staring You
In The Face Near That Phony Gap That
Was Caused By All The Lying, Bad Deals,
Debt, Massive Dilution, And Reverse-Split.

But What Else You Don't See Is More Lies,
More Bad Deals, More Debt, More Dilution,
And Another Reverse-Split . . . LOL

The Only Reason This POS Creeps Up Is
To Help Establish Larger Short Positions.

A Little Up ---> Then A Lot Down


This Company Has A Big
Surprise Waiting For You

N O - P R O F I T
M O R E - D E B T
N O - R E V E N U E S
M O R E - D I L U T I O N
AND ANOTHER REVERSE-SPLIT

That's Right . . .

One Reverse Split Wasn't Enough
Now They Are Promising Two - LOL


:--- (

[ShadowSpy69]

Easily a gap filler $8 and launch to low teens imo is brewing!

[PennystockID2017]

$5 very soon AMRS, don't get shook out its climbing now!!! May see $10 in a few weeks.

[TheSerb]

FACTS BASED ON FLAWED INFORMATION IS NOT CONSIDERED A FACT!

WRONG AGAIN!

AMRS STRONG!

[Spider Web]

WHOOPS - A - DAISY


THEY WILL ALWAYS HAVE DEBT
It Will Take Years To Pay Off The Current Debt
While New Debt Will Then Always Be Added


NEXT TARGET = $1.25
This Target Is The First Major Support Area
Before The Final Drop Below 1 Dollar. Then
On Into Another Reverse-Split Situation,
Which They Are Already Anticipating.


NEW DILUTED SHR STRUCTURE
The Pre-Split OS Was 300 Million.
The Equiv Post-Split Diluted OS
Has Now Increased To 450 Million.

The Pre-Split AS Was 500 Million.
The Equivalent Post-Split AS
Has Now Increased To 3.75 Billion.


JUST TRYING TO GET OUT
They Are Now Set-Up For More Dilution And Another Reverse-Split. It Would Be Wise To Not Believe A Word That This Company Says, Or Any Positive Opinions From Those That Are Trapped And Just Trying To Get Out.


THEY HAVE LOST ALL CONTROL
With All Of Those Bad Collaborations And Back-Room Warrants & Convertible Preferred Stock Deals, The Common Shareholder Is Primed To Be Screwed Over And Over Again With More Dilution And Another Reverse-Split.


MESSED UP AND CONVOLUTED
Any Debt That May Be Cleaned-Up Will Always Be At The Expense Of The Shareholders, Like What Just Recently Happened. The End Game Here May Be To Collapse The Company And Then Reconstruct It Into A Private One, Leaving Everyone Else In The Dust. Most Of The Common People Out There In La-La-Land Cannot Begin To Comprehend The Messed-Up Complexities Of This Convoluted Vast Empty Vacuum, Which Is About To Suck Everyone Down Into Its Deepest Darkest Depths Of Mordor.


THEY ARE LICENSED TO LIE
It Is Just Amazing That Some Federal Authority Has Not Shut This Company Down Yet. Every Amateur PR They Put Out Is Written Under The Guidance Of An Attorney That Keeps Them One Step Away From Larceny. Every PR Is Full Of Holes And Clever Disclaimers. It Is Very Comical To Read And Pick-Apart Every Sentence That They Structure. These People Amount To Nothing More Than Little Thieves And Liars.


FORWARD-LOOKING STATEMENTS
This Company Obviously Relies Heavily On The Hopeful Stupidity Of Emotionally Charged And Easily Manipulated Inexperienced Investors, Along With The Help From Their Flagrant Use Of Forward-Looking Statements .


COMING SOON
ONE DOLLAR AND TWENTY FIVE CENTS
And Then A Break Below One Dollar.
As They Make Their Way To
Another Reverse-Split.


Just My Opinion

[TheSerb]

TRYING TO MAKE SOMETHING OUT OF EVERYTHING HERE!

BOOM!

AMRS!

[Spider Web]

TRYING TO MAKE SOMETHING OUT OF NOTHING

The Bigger They Are The More They Lose ... It Has Been Proven That It Doesn't Matter Who Owns What, Or How Much. They Are All Losers ... It's The Shareholders Who Will Always Be The Ones That Are Being Used Here ... Those Big Players Will Make Money Either Way. And If The Company Goes Bankrupt, They Will Get Paid First. Or They Could Just Buy-Out Whatever Crumbs Are Left, And Screw All Of The Shareholders In The Process Anyway ... The Company Does Not Control Itself Anymore ... With All Of Those Bad Collaboration Deals And Backdoor Warrants And Convertible Preferred Stock Deals, The Common Shareholder Is Primed To Be Screwed Over Again And Again With More Dilution And Another Reverse-Split ... I Have Seldom Seen Anything So Messed Up And Convoluted Before In My Life ... Any Debt That May Be Cleaned-Up Will Always Be At The Expense Of The Shareholders, Like What Just Happened ... The End Game Here May Be To Collapse The Company And Then Reconstruct It Into A Private One, Leaving Everyone Else In The Dust --- Most Common People Out There In La-La-Land Cannot Comprehend The Complexities Of This Vast Empty Vacuum That Is About To Suck Everyone Down Into Its Darkest Depths Of Mordor

JMO

[trubach]

So multi billion dollar company DSM who invested into Amyris at $6.30 per share after 6 weeks of doing DD on Amyris is stupid then. Why would they invest a millions dollars in company who wont give them return? Looks like you are big short here....

[TheSerb]

NOTHING NEGATIVE HERE! KEEP BUYING!


AMRS!!!